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ABSTRACT
Objectives To validate the previously proposed 
classifi cation criteria for Henoch–Schönlein purpura 
(HSP), childhood polyarteritis nodosa (c-PAN), c-Wegener 
granulomatosis (c-WG) and c-Takayasu arteritis (c-TA).
Methods Step 1: retrospective/prospective web-
data collection for children with HSP, c-PAN, c-WG and 
c-TA with age at diagnosis ≤18 years. Step 2: blinded 
classifi cation by consensus panel of a representative 
sample of 280 cases. Step 3: statistical (sensitivity, 
specifi city, area under the curve and κ-agreement) and 
nominal group technique consensus evaluations.
Results 827 patients with HSP, 150 with c-PAN, 60 with 
c-WG, 87 with c-TA and 52 with c-other were compared 
with each other. A patient was classifi ed as HSP in the 
presence of purpura or petechiae (mandatory) with 
lower limb predominance plus one of four criteria: (1) 
abdominal pain; (2) histopathology (IgA); (3) arthritis or 
arthralgia; (4) renal involvement. Classifi cation of c-PAN 
required a systemic infl ammatory disease with evidence 
of necrotising vasculitis OR angiographic abnormalities 
of medium-/small-sized arteries (mandatory criterion) 
plus one of fi ve criteria: (1) skin involvement; (2) myalgia/
muscle tenderness; (3) hypertension; (4) peripheral 
neuropathy; (5) renal involvement. Classifi cation of 
c-WG required three of six criteria: (1) histopathological 
evidence of granulomatous infl ammation; (2) upper 
airway involvement; (3) laryngo-tracheo-bronchial 
involvement; (4) pulmonary involvement (x-ray/CT); 
(5) antineutrophilic cytoplasmic antibody positivity; (6) 
renal involvement. Classifi cation of c-TA required typical 
angiographic abnormalities of the aorta or its main 
branches and pulmonary arteries (mandatory criterion) 
plus one of fi ve criteria: (1) pulse defi cit or claudication; 
(2) blood pressure discrepancy in any limb; (3) bruits; (4) 
hypertension; (5) elevated acute phase reactant.
Conclusion European League Against Rheumatism/
Paediatric Rheumatology International Trials Organisation/
EULAR/PRINTO/PRES criteria for Henoch–Schönlein 
purpura, childhood polyarteritis nodosa, childhood 
Wegener granulomatosis and childhood Takayasu 
arteritis: Ankara 2008. Part II: Final classifi cation 
criteria
Seza Ozen,1 Angela Pistorio,2 Silvia M Iusan,3 Aysin Bakkaloglu,1 Troels Herlin,4 Riva 
Brik,5 Antonella Buoncompagni,3 Calin Lazar,6 Ilmay Bilge,7 Yosef Uziel,8 Donato 
Rigante,9 Luca Cantarini,10 Maria Odete Hilario,11 Clovis A Silva,12 Mauricio Alegria,13 
Ximena Norambuena,14 Alexandre Belot,15 Yackov Berkun,16 Amparo Ibanez Estrella,17 
Alma Nunzia Olivieri,18 Maria Giannina Alpigiani,19 Ingrida Rumba,20 Flavio Sztajnbok,21 
Lana Tambic-Bukovac,22 Luciana Breda,23 Sulaiman Al-Mayouf,24 Dimitrina Mihaylova,25 
Vyacheslav Chasnyk,26 Claudia Sengler,27 Maria Klein-Gitelman,28 Djamal Djeddi,29 
Laura Nuno,30 Chris Pruunsild,31 Jurgen Brunner,32 Anuela Kondi,3 Karaman Pagava,33 
Silvia Pederzoli,3 Alberto Martini,3,34 Nicolino Ruperto3; for the Paediatric Rheumatology 
International Trials Organisation (PRINTO)
▶ Additional data are published 
online only at http://ard.bmj.
com/content/vol69/issue5 
For numbered affi liations see 
end of the article
Correspondence to 
Professor Seza Ozen, Hacettepe 
University Children’s Hospital, 
Department of Pediatric 
Nephrology and Rheumatology, 
Sihhiye, Ankara 06100, Turkey; 
sezaozen@hacettepe.edu.tr
Accepted 21 December 2009
Paediatric Rheumatology European Society propose 
validated classifi cation criteria for HSP, c-PAN, c-WG and 
c-TA with high sensitivity/specifi city.
INTRODUCTION
In 1990 the American College of Rheumatology 
(ACR) proposed classiﬁ cation criteria for patients 
with vasculitides1–5 by analysing 807 adults 
patients with different form of vasculitis: 85 with 
Henoch–Schönlein purpura (HSP), 118 with pol-
yarteritis nodosa (PAN), 85 with Wegener granulo-
matosis (WG), 63 with Takayasu arteritis (TA) and 
456 with other vasculitides (Churg–Strauss, hyper-
sensitivity, giant cell arteritis and other unspeciﬁ ed 
forms).6 Patients with each speciﬁ c vasculitis were 
compared with all the remaining diseases grouped 
into a single control category.
The ACR criteria for HSP (sensitivity 87.1%, 
speciﬁ city 87.7%) require the presence of at least 
two of the following: (1) age ≤20 years at disease 
onset; (2) palpable purpura; (3) acute abdominal 
pain; (4) biopsy showing granulocytes in the walls 
of small arterioles/venules.1
The ACR criteria for PAN (sensitivity 82.2%, 
speciﬁ city 86.6%) require at least three of the 10 
following criteria: (1) granulocyte or mixed leuco-
cyte inﬁ ltrate in an arterial wall on biopsy; (2) 
arteriographic abnormalities; (3) livedo reticularis; 
(4) myalgia; (5) diastolic blood pressure (BP) >90 
mm Hg; (6) mono- or polyneuropathy; (7) ele-
vated blood urea nitrogen or creatinine; (8) testic-
ular pain/tenderness; (9) hepatitis B reactants; (10) 
weight loss >4 kg.3 5
The ACR criteria for WG (sensitivity 88.2%, 
speciﬁ city 92%) require at least two of the fol-
lowing: (1) abnormal urinary sediment (red cell 
casts or >5 red blood cells per high power ﬁ eld); 
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(2) abnormal ﬁ ndings on chest radiograph (nodules, cavities or 
ﬁ xed inﬁ ltrates); (3) oral ulcers or nasal discharge; (4) granuloma-
tous inﬂ ammation on biopsy.4
Finally, the ACR criteria for TA (sensitivity of 91%, speciﬁ city 
98%) require the presence of at least three of the following: (1) 
arteriographic evidence of narrowing or occlusion of the entire 
aorta, its primary branches, or large arteries in the proximal, 
upper or lower extremities; (2) decreased brachial artery pulse; 
(3) claudication of an extremity; (4) systolic BP >10 mm Hg dif-
ference in systolic BP between arms; (5) a bruit over subclavian 
arteries or the aorta; (6) age at disease onset ≤40 years.2 The 
ACR criteria were derived by comparing 63 patients with adult 
TA with 744 controls with other vasculitides.
In 2005 the vasculitis working group of the Paediatric 
Rheumatology European Society (PRES) proposed new 
 classiﬁ cation criteria for paediatric vasculitides, endorsed by the 
European League Against Rheumatism (EULAR).7 However, 
these proposed modiﬁ cations were mainly based on a  literature 
review and a consensus-based process and were not formally 
validated. Thanks to support from EULAR, the Paediatric 
Rheumatology International Trials Organisation (PRINTO)8 and 
PRES, a formal statistical validation process, with a large-scale, 
web-based data collection, was undertaken. The project culmi-
nated ﬁ nally at the 2008 Ankara Consensus Conference which 
had, as its primary objective, the validation of the aforemen-
tioned EULAR-endorsed criteria for paediatric vasculitides.
With this second paper we describe the ﬁ nal classiﬁ cation cri-
teria for each of the four vasculitides analysed (HSP, c-TA, c-PAN 
and c-WG) while the general methodology and overall demo-
graphic and clinical characterisation are reported in the accom-
panying paper.9
PATIENTS AND METHODS
The methodology used is described in detail in the accompa-
nying introduction and methods paper.9 In brief, after obtain-
ing consent from parent(s)/child and ethics committee approval 
as appropriate, 97 PRINTO/PRES institutions in 36 countries, 
enrolled children with vasculitides, into a three-step retrospec-
tive/prospective study.
Step 1: Web-based data collection
Children with age at diagnosis ≤18 years, diagnosed by their 
treating physician, as HSP, c-PAN, c-WG, c-TA or other c- primary 
systemic vasculitis (c-other) were included. Data  collected 
included demographic, diagnosis, signs/symptoms (glossary 
 provided) before/or at the date of diagnosis and at least 3 months 
after, laboratory, histopathological and imaging reports.
Step 2: Classifi cation by consensus panel
Using three Delphi technique10 web-rounds, a subgroup of 
280 cases were classiﬁ ed (blinded to original diagnosis by the 
 treating physician), by a panel of 11 paediatric rheumatologists/
nephrologists into HSP, c-PAN, c-WG, c-TA or c-other. The main 
purpose of the classiﬁ cation exercise was to evaluate the κ level 
of agreement11 12 with 95% CI between the consensus panel 
classiﬁ cation and the attending physician diagnosis.
Step 3: Statistical and consensus evaluations
A nominal group technique10 consensus conference was con-
vened in Ankara in October 2008 to discuss the statistical 
performance (frequency, sensitivity, speciﬁ city, area under the 
curve (AUC) and κ) of clinical/laboratory ﬁ ndings (criteria) and 
of 56 HSP, 29 c-PAN, 62 c-WG and 25 c-TA deﬁ nitions. For the 
purposes of the statistical analysis all cases of speciﬁ c vasculi-
tis (eg, HSP classiﬁ ed by the consensus panel or diagnosed by 
the treating physician) were compared with the control group 
 represented by the remaining cases of childhood vasculitides 
(eg, c-PAN, c-WG, c-TA, c-other).
RESULTS
Of the 1398 children enrolled, 860 (62%) were diagnosed by 
the treating physician as HSP, 172 (12%) as c-PAN, 67 (5%) as 
c-WG, 99 (7%) as c-TA and 200 (14%) as c-other.
Henoch–Schönlein purpura
Step 1: Web-based data collection
From the 860/1398 (62%) children with HSP available in the 
database, 29 patients were excluded from the analysis for the 
following reasons: 16 patients because they were diagnosed 
with infantile haemorrhagic oedema/Finkelstein purpura (all 
aged <1 year), seven because of other co-morbid conditions and 
six for missing data.
Step 2: Classifi cation by consensus panel
Sixty patients (22 difﬁ cult cases and 38 randomly selected) were 
blinded for the referring centre diagnosis and classiﬁ ed by the 
 consensus panel: 56 were conﬁ rmed as HSP while four were 
excluded (in three patients consensus not achieved and one was 
unclassiﬁ able). The κ-agreement between the consensus panel 
and treating physician was 0.96 (95% CI 0.84 to 1), therefore jus-
tifying the inclusion of all 827 patients with HSP in the next step.
Step 3: Statistical and consensus evaluations
The 827/1183 (70%) patients with HSP (771 diagnosed by the 
treating physician and 56 by the consensus panel) were included 
in the ﬁ nal analysis and compared with the remaining 356 patients 
with another form of vasculitides who were used as a control 
group (c-PAN 150, c-WG 60, c-TA 87, c-other 59 patients).
All patients had purpura (lower limb predominance or diffuse 
combined) while the characteristic palpable purpura, commonly 
in crops, with lower limb predominance was seen in 89% of the 
patients with HSP and in 15% of those with c-PAN and c-WG. 
Diffuse abdominal pain was present in 60% of children with HSP, 
arthritis/arthralgia in 78%, proteinuria/haematuria combined in 
33%. IgA deposition was observed in 83/827 (10%) of the HSP 
cases but only 125 patients (89 HSP and 36 controls) had biopsies 
available. There were no other signs and symptoms, laboratory/
biopsy/imaging reports that were more frequently seen in patients 
with HSP than in the other vasculitides (see accompanying paper9 
for further details and online supplementary ﬁ gure 1A web).
Figure 1A shows the sensitivities/speciﬁ cities of patients with 
HSP versus the other c-vasculitides. Purpura with lower limb 
predominance and IgA deposition had both sensitivities/speci-
ﬁ cities >80%; vessel wall granulocytes (ACR criterion) had a 
low speciﬁ city (26%). Abdominal pain had sensitivities/speci-
ﬁ cities >60%, arthritis/arthralgia was sensitive (78%) but less 
speciﬁ c and proteinuria/haematuria was speciﬁ c (70%) but less 
sensitive.
Table 1 provides a glossary of deﬁ nitions, sensitivity/spec-
iﬁ city/AUC for each HSP criterion and the ﬁ nal EULAR/
PRINTO/PRES deﬁ nition. The sensitivities/speciﬁ cities/AUC 
and κ-agreement (between the consensus panel and spe-
ciﬁ c deﬁ nition) of the ﬁ nal HSP EULAR/PRINTO/PRES clas-
siﬁ cation deﬁ nition was 100%/87%/93.5%, respectively, 
with an almost perfect κ-agreement of 0.90 (95% CI 0.84 to 
0.96) compared with 100%/69% of the preliminary EULAR 
HSP proposal. The sensitivity/speciﬁ city of the original HSP 
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45 patients with cutaneous PAN and 14 with microscopic poly-
angiitis were also excluded from the analysis.
Step 3: Statistical and consensus evaluations
The 150/1124 (13%) patients with c-PAN (112 diagnosed by the 
treating physician and 38 by the consensus panel) were included 
in the ﬁ nal analysis and compared with the remaining 974 
patients (HSP 827, c-WG 60, 87 c-TA).
Small- or medium-sized artery necrotising vasculitis was doc-
umented in 28 (19%) and 52 (35%) patients, respectively (small 
or medium in 67 patients, 45%). Angiographic abnormalities 
were present in 64 patients (43%), with 14 (9%) having ste-
noses of medium/small arteries and 57 (38%) aneurysms. The 
presence of necrotising vasculitis or angiographic abnormali-
ties was seen in 116 (77%) of the patients. Among the others 
signs/symptoms the most common was myalgia reported by 
108 (72%) patients. The second clinical characteristic was skin 
involvement observed in 104 (69%) patients with c-PAN versus 
18 (30%) with c-WG; 51 (34%) with livedo reticularis, 84 (56%) 
with skin nodules, 19 (13%) with superﬁ cial skin infarction 
ACR criteria were 100%/2%/51% (κ=0.04), which rose to 
100%/75%/87.5% (κ=0.81) when the age criterion (≤20 years) 
was not considered.
Childhood polyarteritis nodosa
Step 1: Web-based data collection
A total of 172/1398 (12%) children with c-PAN were available 
in the database.
Step 2: Classifi cation of diffi cult cases by consensus panel
Sixty patients (37 difﬁ cult cases and 23 randomly selected) were 
blinded for the referring centre diagnosis and classiﬁ ed by the 
consensus panel: 38 as c-PAN while 22 were excluded (more 
than one reason possible: one because of hepatitis B associa-
tion, two because of incomplete data, 12 because consensus 
was not achieved and 10 because they were unclassiﬁ able). The 
κ-agreement between the consensus panel and treating phy-
sician was 0.73 (95% CI 0.62 to 0.84), therefore justifying the 
inclusion of all 150 patients with c-PAN into the next step. The 
Figure 1 (A) Sensitivity and specifi city values seen in the 827 patients with HSP versus the other forms of childhood vasculitides (c-PAN 150, 
c-WG 60, c-TA 87). (B) Sensitivity and specifi city values seen in the 150 patients with c-PAN versus the other forms of childhood vasculitides 
(HSP 827, c-WG 60, c-TA 87). c-PAN, childhood polyarteritis nodosa; c-TA, c-Takayasu arteritis; c-WG, Wegener granulomatosis; HSP, Henoch–
Schönlein purpura.
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and 16 (11%) with deep skin infarction. Hypertension was 
documented in 44 (29%) patients with c-PAN and in 55 (63%) 
with c-TA. Peripheral neuropathy (mono- or polyneuropathy) 
in 39 (26%) and renal involvement (proteinuria, haematuria 
or red blood cell casts) in 44 (29%). Finally, testicular pain or 
 tenderness was present in 15/75 male children (20%) and signs/
symptoms suggesting vasculitis of any other major organ sys-
tem  (pulmonary, gastrointestinal, cardiovascular, or central ner-
vous system) were reported in 113 (75%). There were no other 
signs and symptoms that were more frequently observed in 
patients with c-PAN than in the other vasculitides (see accom-
panying paper9 for further details and online supplementary 
ﬁ gure 1B).
Figure 1B shows the sensitivities/speciﬁ cities of patients 
with c-PAN versus the other c- vasculitides. Speciﬁ city was 
>99.5% for the mandatory  criteria with sensitivity being 
higher for aneurysm (72%), followed by medium-, small-size 
artery necrotising vasculitis and stenoses. Sensitivity/speciﬁ c-
ity for histopathological changes or angiographic abnormalities 
combined were 90.6%/99.6% in this population. Speciﬁ city of 
the remaining signs/symptoms were>80% with the exception 
of renal involvement (37%), while sensitivity was >70% only 
for skin involvement and myalgia.
Table 2 provides a glossary of deﬁ nitions, sensitivity/speci-
ﬁ city/AUC for each c-PAN criterion and the ﬁ nal EULAR/
PRINTO/PRES deﬁ nition. The sensitivities/speciﬁ cities/AUC 
and κ-agreement (between the consensus panel and speciﬁ c 
deﬁ nition) of the ﬁ nal EULAR/PRINTO/PRES c-PAN classiﬁ ca-
tion deﬁ nition was 89.6%/99.6%/94.6%, respectively, with 
an almost perfect κ-agreement of 0.92 (95% CI 0.86 to 0.98) 
compared with 86.3%/99.6%/93% of the preliminary EULAR 
c-PAN proposal. The sensitivity/speciﬁ city for the original adult 
PAN ACR criteria were 94.7%/95.2%/95% (κ=0.77) in this pae-
diatric population.
Childhood Wegener granulomatosis
Step 1: Web-based data collection
A total 0f 67/1398 (5%) children with c-WG were available in 
the database.
Step 2: Classifi cation of diffi cult cases by consensus panel
Sixty patients (19 difﬁ cult cases and 41 randomly selected) were 
blinded for the referring centre diagnosis and classiﬁ ed by the 
consensus panel: 51 were conﬁ rmed as c-WG (plus one was 
originally diagnosed as c-PAN and one as another form of c-vas-
culitis) while nine were excluded (multiple reasons possible: one 
because age at onset >18 years, one because of other co-mor-
bid conditions, ﬁ ve because consensus was not achieved and 
four because they were classiﬁ ed as c-other). The κ-agreement 
between consensus panel and treating physician was 0.88 (95% 
CI 0.76 to 0.99), therefore justifying the inclusion of all 60 
patients with c-WG in the next step.
Step 3: Statistical and consensus evaluations
The 60/1183 (5%) patients with c-WG (seven diagnosed 
by the treating physician and 53 by the consensus panel) 
were included in the ﬁ nal analysis and compared with the 
 remaining 1123 patients (HSP 827, c-PAN 150, c-TA 87, c-other 
59 patients).
Granulomatous inﬂ ammation lesions were present in 27/50 
patients (54%) (13 in the upper airways, seven kidney, four 
orbital mass, three others). More than 70% of the patients had 
upper airway involvement (either nasal discharge or septum 
perforation or sinus inﬂ ammation), chest x-ray or CT signs 
(47/60 patients, 78%), versus <10% in the other vasculitides. 
Immunoﬂ uorescence antineutrophilic cytoplasmic antibody 
(ANCA) was positive in 47 (78%) patients, MPO/pANCA in 
14 (23%) and PR3/cANCA in 38 (63%) (any ANCA positiv-
ity in 54, 90%) while the frequency of any ANCA positivity 
was 11% in c-PAN and <5% in the other vasculitides. Renal 
involvement was observed in 39 (65%) of the patients with 24 
(40%) patients having necrotising pauci-immune glomerulone-
phritis. There were no other signs and symptoms, laboratory/
biopsy/imaging reports that were more frequently observed in 
patients with c-WG than in the other vasculitides (see accom-
panying paper9 for further details and online supplementary 
ﬁ gure 2A).
Figure 2A shows the sensitivities/speciﬁ cities of patients 
with c-WG versus the other c-vasculitides. Sensitivities/speci-
ﬁ cities were >75% for upper airway involvement, pulmonary 
Table 1 Final EULAR/PRINTO/PRES HSP criteria (with glossary) and classifi cation defi nition (sample 973)
Criterion Glossary Sensitivity (%) Specifi city (%) AUC (%)
Purpura (mandatory criterion) Purpura (commonly palpable and in crops) or petechiae, with lower limb predominance,
* not related to thrombocytopenia
89 86 87.5
 1. Abdominal pain Diffuse abdominal colicky pain with acute onset assessed by history and physical 
examination. May include intussusception and gastrointestinal bleeding
61 64 62.2
 2. Histopathology Typically leucocytoclastic vasculitis with predominant IgA deposit or proliferative 
glomerulonephritis with predominant IgA deposit
93 89 91.1
 3. Arthritis or arthralgias Arthritis of acute onset defi ned as joint swelling or joint pain with limitation on motion
Arthralgia of acute onset defi ned as joint pain without joint swelling or 
limitation on motion
78 42 59.9
 4. Renal involvement Proteinuria >0.3 g/24 h or >30 mmol/mg of urine albumin/creatinine ratio on a spot 
morning sample
Haematuria or red blood cell casts: >5 red blood cells/high power fi eld or red blood cells 
casts in the urinary sediment or ≥2+ on dipstick
33 70 51.4
HSP EULAR/PRINTO/PRES 
Ankara 2008 classifi cation 
defi nition: κ 0.90 (95% CI 0.84 
to 0.96)
Purpura or petechiae (mandatory) with lower limb predominance* and at least one of the 
four following criteria:
Abdominal pain
Histopathology
Arthritis or arthralgia
Renal involvement
100 87 93.5
*For purpura with atypical distribution a demonstration of an IgA deposit in a biopsy is required.
AUC, area under the curve; EULAR, European League Against Rheumatism; HSP, Henoch–Schönlein purpura; PRES, Paediatric Rheumatology European Society, PRINTO, Paediatric 
Rheumatology International Trials Organisation.
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involvement on chest x-ray or CT and ANCA (sensitivities/
speciﬁ cities immunoﬂ uorescence 84%/91%, MPO 26%/94%, 
PR3 69%/96%).
Table 3 provides the glossary of deﬁ nitions, sensitivity/
speciﬁ city/AUC for each c-WG criterion and the ﬁ nal EULAR/
PRINTO/PRES deﬁ nition. The sensitivities/speciﬁ cities of 
the ﬁ nal 2009 EULAR/PRINTO/PRES classiﬁ cation deﬁ nition 
were 93.3%/99.2%/96.3%, respectively, with an almost per-
fect κ-agreement of 0.90 (95% CI 0.84 to 0.97) compared with 
88%/100%/94% for the preliminary EULAR c-WG  proposal. 
The sensitivities/speciﬁ cities of the original adult WG ACR 
criteria were 83%/98%/90.5% (κ=0.77) in this paediatric 
population.
Childhood Takayasu arteritis
Step 1: Web-based data collection
A total of 99/1398 (7%) children with c-TA were available in 
the database.
Step 2: Classifi cation of diffi cult cases by consensus panel
Sixty patients (10 difﬁ cult cases and 50 randomly selected) were 
blinded for the referring centre diagnosis and classiﬁ ed by the 
consensus panel: 48 as c-TA while 12 were excluded (multiple 
reasons possible: two because age at onset was >18 years, 
one because of incomplete data, nine because consensus was 
not achieved and three because they were unclassiﬁ able). The 
κ-agreement between consensus panel and treating physician 
was 0.84 (95% CI 0.73 to 0.96) therefore justifying the inclusion 
of all 87 patients with c-TA in the next step.
Step 3: Statistical and consensus evaluations
The 87/1183 (7%) patients with c-TA (39 diagnosed by the 
treating physician and 48 by the consensus panel) were included 
in the ﬁ nal analysis and compared with the remaining 1096 
patients with other form of vasculitides (HSP 827, c-PAN 150, 
c-WG 60, other forms 59 patients).
All 87 patients had angiographic abnormalities (100%) (for three 
patients stenoses were documented by MRI or CT), of whom 74 
(85%) had stenoses and 43 (49%) aneurysms. Decreased periph-
eral artery pulse(s) were observed in 62 (71%) and  claudication 
of extremities in 33 (38%) (either signs in 65 patients, 75%). 
Discrepancy of four limb BP >10 mm Hg, bruits over aorta and/
or its major branches were reported in 54 (62%) and 50 (57%) 
patients, respectively. Also, hypertension was  present in 55 
(63%) children as compared with the 44 (29%) patients with 
c-PAN and six (10%) with WG. Abnormal acute phase  reactants 
 (erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP)) 
were observed, at the time of diagnosis, in 76 (87%), similar to 
c-PAN and c-WG. There were no other signs and symptoms that 
were more frequently observed in patients with c-TA than in the 
other vasculitides (see accompanying paper9 for further details 
and online supplementary ﬁ gure 2B).
Table 2 Final EULAR/PRINTO/PRES c-PAN criteria (with glossary) and classifi cation defi nition (sample 1099)
Criterion Glossary Sensitivity (%) Specifi city (%) AUC (%)
A systemic infl ammatory disease characterised by:
Histopathology  Evidence of necrotising vasculitis in medium or small sized arteries 84.8 99.7 92.3
Angiographic abnormalities   Angiography showing aneurysm, stenoses or occlusion of a medium or small 
sized artery, not due to fi bromuscular dysplasia, or other non-infl ammatory causes.
 Conventional angiography is the preferred imaging modality.
81.0 99.9 90.5
(Histopathology or angiography are mandatory criterion) 90.6 99.6 95.1
 1. Skin involvement Livedo reticularis: purplish reticular pattern usually irregularly distributed around 
subcutaneous fat lobules, often more prominent with cooling
Skin nodules: tender subcutaneous nodules
Superfi cial skin infarctions: superfi cial skin ulcers (involving skin and superfi cial 
subcutaneous tissue) or other minor ischaemic changes (nailbed infarctions, splint 
haemorrhages, digital pulp necrosis)
Deep skin infarctions: deep skin ulcers (involving deep subcutaneous tissue and 
underlying structures), digital phalanx or other peripheral tissue (nose and ear tips) 
necrosis/gangrene
78.8 94.3 86.6
 2.  Myalgia or muscle 
tenderness
Muscle pain or tenderness 72.5 83.6 78.1
 3. Hypertension Systolic/diastolic blood pressure greater than 95th centile for height 29.7 89 59.4
 4. Peripheral neuropathy Sensory peripheral neuropathy: neuropathy resulting in glove or stocking distribution of 
sensory loss
Motor mononeuritis multiplex Neuritis of named peripheral nerve, only scored if motor 
involvement
26.0 99.8 62.9
 5. Renal involvement Proteinuria >0.3 g/24 h or >30 mmol/mg of urine albumin/creatinine ratio on a spot 
morning sample
Haematuria or red blood cell casts: >5 red blood cells/high power fi eld or red blood cells 
casts in the urinary sediment or ≥2+ on dipstick
Impaired renal function: measured or calculated GFR (Schwartz formula) 
<50% normal
37.3 36.7 37
c-PAN EULAR/PRINTO/PRES 
Ankara 2008 classifi cation 
defi nition: κ 0.92 (95% CI 0.86 
to 0.98)
Histopathology or angiographic abnormalities (mandatory) plus one of the fi ve following 
criteria:
Skin involvement
Myalgia/muscle tenderness
Hypertension
Peripheral neuropathy
Renal involvement
89.6 99.6 94.6
AUC, area under the curve; c-PAN, childhood polyarteritis nodosa; EULAR, European League Against Rheumatism; GFR, glomerular fi ltration rate; PRES, Paediatric Rheumatology 
European Society, PRINTO, Paediatric Rheumatology International Trials Organisation.
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Figure 2B shows the sensitivities/speciﬁ cities of patients with 
c-TA versus the other c-vasculitides. Stenoses had higher sensi-
tivities/speciﬁ cities (85%/100%) than aneurysms (49%/99.9%) 
(stenoses or aneurysm 100%/99.9%). The other four features 
showed a speciﬁ city of ≥90%, while sensitivity was >70% 
only for pulse deﬁ cit/claudication. Sensitivities/speciﬁ cities of 
abnormal acute phase reactants (ESR<20 or CRP elevated) were 
95%/14%.
Table 4 provides a glossary of deﬁ nitions, sensitivity/spec-
iﬁ city/AUC for each c-TA criterion and the ﬁ nal EULAR/
PRINTO/PRES deﬁ nition. The sensitivity/speciﬁ city/AUC 
of the ﬁ nal EULAR/PRINTO/PRES classiﬁ cation deﬁ nition 
was 100%/99.9%/99.95%, respectively, with an almost per-
fect κ-agreement of 0.99 (95% CI 0.93 to 1) compared with 
94.3%/99.9%/97.1% of the preliminary EULAR c-TA proposal. 
The sensitivities/speciﬁ cities for the original adult TA ACR cri-
teria were 85.1%/99.6%/92.4% (κ=0.89) in this paediatric pop-
ulation with a decrease in sensitivity if the age criterion (<40 
years) was removed.
Further results on sensitivities, specifi cities, 
AUC and κ-agreement
In order to control for potential skewing of data we repeated 
the analysis with a random sample of 120 patients with HPS 
instead of the full 827 sample. Sensitivities, speciﬁ cities, AUC 
and κ-agreement of the ﬁ nal classiﬁ cation criteria, as well as of 
the individual criterion for HSP, c-PAN, c-WG and c-TA did not 
change when a random sample of 120 patients with HSP was 
used instead of the full 827 HSP sample (data not shown).
DISCUSSION
The diagnosis of classic HSP is commonly made by paediatri-
cians. However, validated classiﬁ cation criteria did not exist. 
This is crucial for future collaborative studies, which require 
standardised criteria. While there are some similarities between 
the original ACR criteria and the new criteria (eg, purpura and 
abdominal pain), some changes were also considered. The ACR 
criteria required biopsy showing granulocytes in the walls of 
arterioles or venules; however, this criterion had a very low 
Figure 2 (A) Sensitivity and specifi city values seen in the 60 patients with c-WG versus the other forms of childhood vasculitides (HSP 827, c-PAN 
150, c-TA 87). (B) Sensitivity and specifi city values seen in the 87 patients with c-TA versus the other forms of childhood vasculitides (HSP 827, 
c-PAN 150, c-WG 60). ANCA, antineutrophilic cytoplasmic antibody; c-PAN, childhood polyarteritis nodosa; CRP, C-reactive protein; c-TA, c-Takayasu 
arteritis; c-WG, Wegener granulomatosis; ESR, erythrocyte sedimentation rate; HSP, Henoch–Schönlein purpura.
04_annrheumdis116657.indd   803 4/7/2010   3:14:34 PM
group.bmj.com on October 21, 2015 - Published by http://ard.bmj.com/Downloaded from 
Criteria
Ann Rheum Dis 2010;69:798–806. doi:10.1136/ard.2009.116657804
on the borders of cutaneous PAN, which constitutes a large 
group in paediatric practice.13 We have not included in the 
analysis microscopic polyangiitis and cutaneous c-PAN since 
data related to these two subgroups of the disease were few 
and since they were empirically deﬁ ned in the 2005 EULAR/
PRES criteria.
For c-WG the main differences from the ACR criteria were the 
addition of chest CT scan results, the inclusion of ANCA pos-
itivity and more speciﬁ c items for upper and lower respiratory 
involvement. These additions were thought to be important 
since c-WG has some features such as more frequent subglottic 
stenoses that differentiate it from the adult form.14 Very minor 
changes were made to the original 2005 EULAR/PRES c-WG 
that includes any detected ANCA (immunoﬂ uorescence/MPO/
PR3) as a positive ﬁ nding. Thus, the ﬁ nal EULAR/PRINTO/PRES 
deﬁ nition had a slight increase in speciﬁ city compared with the 
preliminary 2005 EULAR-endorsed c-WG criteria.7 Also, the 
sensitivity/speciﬁ city of the ﬁ nal deﬁ nition was higher than the 
original ACR criteria as also reported recently by Cabral et al15 
who used, as control group, other ANCA-associated vasculitides. 
At the Ankara Consensus Conference limited forms of c-WG, 
such as isolated orbital/retro-orbital disease or limited upper air-
way involvement, were speciﬁ cally considered and it was agreed 
they should be dealt with in the future separately from the more 
widespread form of the disease. Similarly, it was not possible 
to formally differentiate c-WG from microscopic polyangiitis 
and Churg–Strauss syndrome since too few cases were avail-
able in the dataset. Thus, at present, the approach suggested by 
Watts et al16 to differentiate between WG and microscopic poly-
angiitis could be applied to children since the surrogate markers 
described in his classiﬁ cation algorithm are also included in their 
classiﬁ cation.
For c-TA, angiographic ﬁ ndings are crucial in the diagnosis 
and thus this criterion had already been deﬁ ned as mandatory 
in the 2005 EULAR/PRES7 c-TA criteria. We had also consid-
ered more recent imaging modalities, such as CT or MRI, 
which were not considered at the time the ACR criteria were 
published. Indeed, arteriographic abnormalities were present 
speciﬁ city in this paediatric population. On the other hand, 
although biopsies were rarely done, the presence of IgA in the 
biopsy was very speciﬁ c. Thus the consensus panel chose his-
topathology showing typically leucocytoclastic vasculitis with 
predominant IgA deposit or proliferative glomerulonephritis 
with predominant IgA deposit for all doubtful cases such as for 
purpura with atypical characteristics or distribution. Other dif-
ferences were related to the inclusion of joint involvement that 
is more common and with higher sensitivity in children than in 
the patients of the ACR paper.1 Renal involvement was also con-
sidered worth including to underline the importance of prospec-
tive monitoring for haematuria/proteinuria when HSP evolves 
to severe renal damage. The ﬁ nal HSP deﬁ nition had greater 
sensitivity than the preliminary 2005 EULAR-endorsed criteria,7 
with a substantial κ-agreement with the blinded evaluation of 
difﬁ cult cases by the consensus panel. Although the sensitivity 
and speciﬁ city of the ACR was >87% in the subjects analysed 
in the original paper,1 the speciﬁ city dropped dramatically in our 
sample because all patients had, by inclusion criteria, an age <18 
years; indeed, the speciﬁ city rose to 75% when the age criterion 
was removed.
For the diagnosis of c-PAN, histopathological and angio-
graphic ﬁ ndings are crucial and for this reason this combined 
criterion was already mandatory in the 2005 EULAR/PRES7 cri-
teria. During the discussion there was a speciﬁ c concern about 
the imaging modalities to be used in children owing to the 
recent advances in these techniques. Although conventional 
angiogram remains the current ‘gold standard’, it is an invasive 
technique especially in young children where the problem of 
radiation should also be considered. The group is aware that 
imaging modalities are advancing rapidly. Future studies may 
establish a place for non-invasive angiographic techniques. 
The major change to the original 2005 EULAR/PRES-endorsed 
c-PAN criteria was the removal of the criteria for the signs and 
symptoms for vasculitis in speciﬁ c organ systems and testicu-
lar pain or tendernes; this change led to an increase of the sen-
sitivity and to a simpliﬁ cation of the ﬁ nal criteria. A special 
challenge in the classiﬁ cation of PAN is the lack of consensus 
Table 3 Final EULAR/PRINTO/PRES c-WG criteria (with glossary) and classifi cation defi nition (sample 939)
Criterion Glossary Sensitivity (%) Specifi city (%) AUC (%)
 1. Histopathology Granulomatous infl ammation within the wall of an artery or in the perivascular 
or extravascular area
54 99.6 76.8
 2. Upper airway involvement Chronic purulent or bloody nasal discharge or recurrent epistaxis/crusts/
granulomata
Nasal septum perforation or saddle nose deformity
Chronic or recurrent sinus infl ammation
83 99 91
 3.  Laryngo-tracheo-bronchial 
involvement
Subglottic, tracheal or bronchial stenoses 22 99.8 60.7
 4. Pulmonary involvement Chest x-ray or CT showing the presence of nodules, cavities or fi xed infi ltrates 78 92 85.2
 5. ANCA ANCA positivity by immunofl uorescence or by ELISA (MPO/p or PR3/c ANCA) 93 90 91.7
 6. Renal involvement Proteinuria >0.3 g/24 h or >30 mmol/mg of urine albumin/creatinine ratio 
on a spot morning sample
Haematuria or red blood cell casts: >5 red blood cells/high power fi eld or 
red blood cells casts in the urinary sediment or ≥2+ on dipstick
Necrotising pauci-immune glomerulonephritis
65 69.6 67.3
c-WG EULAR/PRINTO/PRES 
Ankara 2008 classifi cation 
defi nition: κ 0.90 (95% CI 0.84 
to 0.97)
At least three of the six following criteria:
Histopathology
Upper airway involvement
Laryngo-tracheo-bronchial stenoses
Pulmonary involvement
ANCA positivity
Renal involvement
93.3 99.2 96.3
ANCA, antineutrophilic cytoplasmic antibody; AUC, area under the curve; c-WG, c-Wegener granulomatosis; EULAR, European League Against Rheumatism; PRES, Paediatric 
Rheumatology European Society, PRINTO, Paediatric Rheumatology International Trials Organisation.
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in 41% of the children and this ﬁ gure rose to 100% when we 
considered all imaging modalities. During the consensus discus-
sion special emphasis was placed on the differential diagnosis 
of non-inﬂ ammatory conditions such as ﬁ bromuscular dysplasia 
or mid-aortic syndrome for which future imaging technologies 
may be of help. Other differences from the ACR were the com-
bination of pulse deﬁ cit and claudication, which were both very 
frequent (75%) and highly speciﬁ c, the addition of hypertension 
(more frequent than in the other c-vasculitides) and the removal 
of the age limit criterion. Moreover, the addition of increased 
acute phase reactants as an extra criterion, led us to properly 
classify all cases in which this laboratory sign, associated with 
angiographic abnormalities, was an important ﬁ nding before 
the onset of complications such as hypertension or pulse deﬁ -
cit or claudication. Together, these changes increased the sensi-
tivity to 100% and the κ-agreement reached between the ﬁ nal 
 classiﬁ cation deﬁ nition and the consensus panel choice was very 
close to 1. It should be noted that in children, TA is a distinct 
and unique entity while by contrast in adult disease, relatively 
younger patients with giant cell arteritis and relatively older 
patients with TA may cause some difﬁ culty in classiﬁ cation.
The main advantage of the proposed deﬁ nitions lies in the 
worldwide data collection that ensures greater variability of 
the cases examined, as well as in full validation testing that 
 combined both statistics and consensus formation processes. 
The ﬁ nal EULAR/PRINTO/PRES criteria had an overall bet-
ter performance for all four diseases, with substantially bet-
ter speciﬁ city for deﬁ ning the disease. They also all reached a 
κ-agreement of >0.80 between the ﬁ nal classiﬁ cation deﬁ ni-
tion and the  consensus panel. Thus we suggest that, at least in 
 children, they are superior to the previously existing criteria. 
With these new validated classiﬁ cation criteria we can start plan-
ning multicentre studies similar to those carried out by EUVAS, 
and gathering our expertise and knowledge so that we can serve 
these children better. It should be emphasised, however, that 
the proposed deﬁ nitions are not diagnostic criteria but rather 
classiﬁ cation criteria.
In conclusion EULAR/PRINTO/PRES propose validated clas-
siﬁ cation criteria for HSP, c-PAN, c-WG and c-TA with high 
sensitivity/speciﬁ city.
Table 4 Final EULAR/PRINTO/PRES c-TA criteria (with glossary) and classifi cation defi nition (sample 1056)
Criterion Glossary Sensitivity (%) Specifi city (%) AUC (%)
Angiographic abnormality 
(mandatory criterion)
Angiography (conventional, CT, or MRI) of the aorta or its main branches and 
pulmonary arteries showing aneurysm/dilatation, narrowing, occlusion or 
thickened arterial wall not due to fi bromuscular dysplasia, or similar causes; 
changes usually focal or segmental
100 99.9 99.9
 1. Pulse defi cit or claudication Lost/decreased/unequal peripheral artery pulse(s)
Claudication: focal muscle pain induced by physical activity
74.7 99.1 86.9
 2.  Blood pressure (BP) 
discrepancy
Discrepancy of four limb systolic BP >10 mm Hg difference in any limb. 63.5 99.6 81.6
 4. Bruits Audible murmurs or palpable thrills over large arteries 58.8 99.8 79.3
 5. Hypertension Systolic/diastolic BP greater than 95th centile for height 63.2 90.5 76.8
 6. Acute phase reactant Erythrocite sedimentation rate >20 mm per fi rst hour or CRP any value above 
normal (according to the local laboratory)
95.0 14.1 54.6
c-TA EULAR/PRINTO/PRES 
Ankara 2008 classifi cation 
defi nition: κ 0.99 (95% CI 0.93 to 
1.00)
Angiographic abnormalities of the aorta or its main branches and pulmonary 
arteries showing aneurysm/dilatation (mandatory criterion) plus one of the fi ve 
following criteria:
Pulse defi cit or claudication
Four limbs BP discrepancy
Bruits
Hypertension
Acute phase reactant
100 99.9 99.9
AUC, area under the curve; CRP, C-reactive protein; c-TA, c-Takayasu arteritis; EULAR, European League Against Rheumatism; PRES, Paediatric Rheumatology European Society; 
PRINTO, Paediatric Rheumatology International Trials Organisation.
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